|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's range||44.48 - 49.75|
|52-week range||36.91 - 58.10|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||18.05|
|Forward dividend & yield||1.75 (3.89%)|
|Ex-dividend date||26 May 2022|
|1y target est||58.50|
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
A US judge has dismissed thousands of lawsuits claiming that popular heartburn medication Zantac causes cancer, handing a big victory to pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim. US District Judge Robin Rosenberg in West Palm Beach, Florida, said in an order on Tuesday that the almost 2,500 lawsuits filed in federal court by plaintiffs were based on flawed science, and that the only reliable testing of the blockbuster drug undertaken showed an “unprovable risk of cancer”.
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.